跳转至内容
Merck
CN

PZ0330

Sigma-Aldrich

达科替尼

≥98% (HPLC)

别名:

PF-00299804, PF-00299804-03, PF-299, (2E)-N- [4-[(3-氯-4-氟苯基)氨基] -7-甲氧基-6-喹唑啉基] -4-(1-哌啶基)-2-丁烯酰胺

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C24H25ClFN5O2
分子量:
469.94
UNSPSC代码:
41106609
NACRES:
NA.77

质量水平

检测方案

≥98% (HPLC)

形式

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

room temp

InChI

1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+

InChI key

LVXJQMNHJWSHET-AATRIKPKSA-N

生化/生理作用

达克替尼(PF-00299804)是不可逆的 EGFR 抑制剂和抗肿瘤药。 它是 HER-1(EGFR),-2 和 -4 酪氨酸激酶的有效抑制剂,对 EGFR、ERBB2 和 ERBB4 的 IC50 分别为 6.0、45.7 和 73.7 nM。 人们相信达克替尼通过在 ATP 位点结合和 erbB 家族成员催化域中亲核半胱氨酸残基的共价修饰,不可逆地抑制 erbB 酪氨酸激酶活性。

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jeffrey A Engelman et al.
Cancer research, 67(24), 11924-11932 (2007-12-20)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective treatments for a subset of non-small cell lung cancers. In particular, cancers with specific EGFR-activating mutations seem to be the most sensitive to these agents. However, despite
Yutaro Yamamoto et al.
Acta histochemica et cytochemica, 52(6), 101-106 (2020-02-01)
Dacomitinib, a second-generation tyrosine kinase inhibitor, was irreversible inhibitor forming covalent bonds with the kinase domains of EGFR and other ErbB family receptors. Dacomitinib has been approved for the treatment of locally advanced or metastatic non-small cell lung cancer. In
Andrea J Gonzales et al.
Molecular cancer therapeutics, 7(7), 1880-1889 (2008-07-09)
Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types. Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus
Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.
Ronan J Kelly et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(28), e507-e510 (2010-08-04)
Abram Calderon et al.
Oncotarget, 11(46), 4224-4242 (2020-11-28)
KSHV-associated cancers have poor prognoses and lack therapeutics that selectively target viral gene functions. We developed a screening campaign to identify known drugs that could be repurposed for the treatment of KSHV-associated cancers. We focused on primary effusion lymphoma (PEL)

商品

Discover definitions and uses for irreversible inhibitors including the types of irreversible inhibitors: suicide inhibitors, heavy metal inhibitors, and time-dependent inhibitors.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门